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Abstract: Background: Understanding mechanisms underlying specific chemotherapeutic responses in subtypes of
cancer may improve identification of treatment strategies most likely to benefit particular patients. For example,
triple-negative breast cancer (TNBC) patients have variable response to the chemotherapeutic agent cisplatin.
Understanding the basis of treatment response in cancer subtypes will lead to more informed decisions about
selection of treatment strategies.
Methods: In this study we used an integrative functional genomics approach to investigate the molecular
mechanisms underlying known cisplatin-response differences among subtypes of TNBC. To identify changes in gene
expression that could explain mechanisms of resistance, we examined 102 evolutionarily conserved cisplatin-associated
genes, evaluating their differential expression in the cisplatin-sensitive, basal-like 1 (BL1) and basal-like 2 (BL2) subtypes,
and the two cisplatin-resistant, luminal androgen receptor (LAR) and mesenchymal (M) subtypes of TNBC.
Results: We found 20 genes that were differentially expressed in at least one subtype. Fifteen of the 20 genes are
associated with cell death and are distributed among all TNBC subtypes. The less cisplatin-responsive LAR and M TNBC
subtypes show different regulation of 13 genes compared to the more sensitive BL1 and BL2 subtypes. These 13 genes
identify a variety of cisplatin-resistance mechanisms including increased transport and detoxification of cisplatin, and
mis-regulation of the epithelial to mesenchymal transition.
Conclusions: We identified gene signatures in resistant TNBC subtypes indicative of mechanisms of cisplatin. Our results
indicate that response to cisplatin in TNBC has a complex foundation based on impact of treatment on distinct cellular
pathways. We find that examination of expression data in the context of heterogeneous data such as drug-gene
interactions leads to a better understanding of mechanisms at work in cancer therapy response.
Keywords: Triple-negative breast cancer, TNBC, Cisplatin, Cisplatin sensitivity, Cancer subtypes, Gene expression, Cancer
genomics, Drug response, Functional genomics, Data mining

Background
A major goal of improved classification of cancer
subtypes is to stratify patient populations and to more
rapidly identify effective treatment strategies. Advances
in molecular characterization of tumors not only improve classification, but also point directly to molecular
mechanisms that lead to different therapeutic responses.
By integrating heterogenous functional genomic data on
tumor subtype characteristics, with known mechanisms
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and pathways and molecular response to drugs, it is possible to match drug response to tumor characteristics,
thus refining treatment options.
Subtypes of TNBC

Classification of cancer subtypes relies on many criteria
including histological typing, mutation status, genomic
structural variations and expression profiling [1–5].
Breast cancers are often classified by the presence or
absence of three receptors: estrogen receptor (ESR1),
progesterone receptor (PGR), and the HER2 epidermal
growth factor receptor (ERBB2) [6, 7]. Tumors that lack
expression of all three receptors are called triple-
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negative breast cancer (TNBC). As many available therapies in breast cancer target one of these receptors,
TNBC status limits treatment options. TNBC is particularly aggressive with higher rates of recurrence, metastasis, and mortality than other breast cancers [8, 9].
Additionally, breast cancers are typically classified as
luminal, basal/myoepithelial or ERBB2- subtypes based
on relation to cell types found in the normal breast [10].
Although most TNBC cancers are characterized as
basal-like, about 20% of TNBC tumors are classified as
non-basal [11].
Two recent studies have classified TNBCs based on
clustering genes that are up and down-regulated resulting in six and four molecularly defined subtypes, respectively [4, 5]. Lehmann et al. initially described and
tested chemotherapy response in six TNBC subtypes:
basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like
(MSL) and luminal androgen receptor (LAR) [4]. In another study, Burstein et al. also used gene-expression
profiling to subclassify TNBC into four subtypes: mesenchymal (MES), luminal AR (LAR), basal-like immune
suppressed (BLIS) and basal-like immune activated
(BLIA) [5]. Burstein et al. compared their classifications
with the Lehmann classifications and showed that there
was some concordance with the LAR/LAR, MSL/MES
and M/BLIS type tumors from both groups, but little
discrimination of the BL1, BL2 and IM subtypes [5]. For
our analysis, we used sets from four of the subtypes
described by Lehmann et al: BL1, BL2, M, and LAR [12]
(more details below).

and curated data associating cisplatin with interacting
genes provides a robust data collection for integrated
analysis. This provides a unique opportunity to study the
genetic mechanisms that underlie TNBC subtypes and
their relation to cisplatin.
Currently, 22 clinical trials are exploring the use of
cisplatin to treat TNBC either as a single agent or in
combination with other therapies [19] (Search criteria
were: not yet recruiting, recruiting, enrolling by invitation, and active, not recruiting accessed 01/22/
2019). In particular, use of cisplatin therapy has been
suggested for TNBC harboring a BRCA mutation [17].
Cisplatin is a DNA-intercalating agent that cross-links
DNA resulting in interference with RNA transcription
and DNA replication activities. If the DNA lesions are
not repaired, DNA-damage induced cell-cycle arrest
and apoptosis are triggered [20, 21]. Cells can become
resistant to cisplatin by several mechanisms including
change in the accumulation of the drug in cells either
by inhibited uptake or enhanced efflux, detoxification
of the drug by redox mechanisms, repair of the DNA
by excision repair mechanisms, or negative regulation
of apoptotic mechanisms [22–25].
Relevance
New insights into the biological processes associated
with cisplatin in different molecular subtypes of TNBC
may lead to [1] a better understanding of the mechanisms underlying treatment response differences, [2]
strategies for identifying those patients that are more
likely to respond robustly to chemotherapy, and [3] the
identification of new treatment strategies.

Treatment of TNBC

Approach

There are no targeted treatments for TNBC [13]. Standard treatment for TNBC patients includes chemotherapy
and surgery and patients often become refractory to the
treatment [14, 15]. Patients that achieve a complete
response during neoadjuvant therapy generally have
better outcomes [16]. Recent strategies for the treatment
of TNBC define different treatments depending on
BRCA gene status and CD274 (PD-L1) expression status
[17]. Treatments addressed include chemotherapy, immunotherapy, and PARP inhibitor therapy. First-line
chemotherapeutic agents include taxane and anthracycline, which can be used singly or in combination, but
these agents can be augmented with other treatments in
cases of progression or contraindications [17].

Our approach is to integrate and analyze curated information from pathways and mechanisms obtained in
multiple species with empirical data collected in tumor
profiling and mechanistic experiments. This allows us
to focus, in a ‘sea’ of differentially expressed genes, on
genes related to specific areas of interest--in our case
genes related to the biology of cisplatin. In this study,
we used the GeneWeaver (GW) gene set analysis platform [26] to identify specific biological processes that
could explain the observation that of the TNBC subtypes, BL1 and BL2 are more sensitive to cisplatin than
M and LAR [4]. We focus on these four subtypes because the MSL and IM subtypes were later shown to
contain stromal cells and infiltrating lymphocytes respectively [12]. GW comprises a database of gene sets
from multiple functional genomics data resources, curated publications and user submisisons. These data resources are provided with a suite of combinatorial and
statistical tools for performing set operations on user
selected gene lists. This provided a platform for the
comparison of genomic profiles of multiple TNBC

TNBC and Cisplatin

Although not currently considered standard of care for
TNBC, there is renewed interest in cisplatin use to treat
TNBC [18]. Cisplatin has been in use for over 40 years
to treat multiple types of cancer. Substatial data correlating cisplatin sensitivity with respect to TNBC subtypes
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subtypes and gene products with a chemotherapeutic
drug. To create the gene sets for our study we first
identified evolutionarily conserved genes that were
associated with cellular or physiological responses to
cisplatin. We then identified which of the genes in the
conserved cisplatin-associated set were found among
genes shown previously to be differentially expressed in
TNBC molecular subtypes. Finally, we analyzed the differentially expressed, cisplatin-associated genes with respect to biological processes and to pathways associated
with sensitivity or resistance to cisplatin (Fig. 1).

Methods
Gene sets

To investigate these genes in the context of TNBC, we
expanded the gene-set collection in GW by constructing
genes sets for the differentially regulated genes described
by Lehmann et al., [4], thereby making gene sets for
identified up- and down-regulated genes for each of the
six molecular subtypes of TNBC. For our analysis, we
used sets from four of the subtypes that were subsequently shown not to contain infiltrating cells: BL1, BL2,
M, and LAR [12].
For all gene sets, we used Human Genome Nomenclature Committee (HGNC)-approved identifiers. Genes
that we could not unambiguously assign to an HGNC
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identifier were not included. Details of the source and
methods of curation are reported for each of the gene
set descriptions as part of the GW record. For ontologytagging, TNBC-gene sets were annotated with the
Disease Ontology term ‘triple-receptor negative breast
cancer’ (DOID:0060081), and the Human Phenotype
Ontology term ‘Breast carcinoma’ (HP:0003002) ([27,
28], respectively). Gene sets with known response to cisplatin were tagged with the Chemicals of Biological
Interest (ChEBI) term ‘cisplatin’ (CHEBI:27899) [29].
To create a set of human genes associated with cisplatin that are evolutionarily conserved, we identified
gene sets associated with studies of cisplatin in GW’s
database and applied combinatorial tools to selected sets
as outlined below [30] (Fig. 2).
Using existing gene sets in GW we identified 34
cisplatin-associated gene sets that included sets obtained
from GWAS studies (22 sets), MESH terms (2 sets) and
the Comparative Toxicogenomics Database (CTD) (10
sets) respectively. CTD curates many aspects of genechemical interactions including regulatory, physical
interaction, responses, and interactions that are reported
as a result of interactions of cisplatin combined with
other treatments [31]. The provenance of chemical-gene
associations is fully traceable back to the original source.
For eample the association of the gene RAD51 with

Fig. 1 Title: Workflow to Identify Cisplatin-Related Processes in TNBC Subtypes. Legend: Summary of the strategy we used to identify cisplatinrelated processes that are up and down-regulated in TNBC subtypes using the gene sets GS125959, GS257116 and GS263765. 1. Create a set of
evolutionarily conserved genes that are associated with cisplatin. 2. Identify the conserved set of cisplatin-responsive genes that are differentially
regulated in the TNBC subtypes. 3. Determine the GO biological processes and individual cisplatin-related processes that are enriched in the
overlap set.
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Fig. 2 Title: GW Gene Sets Related to Cisplatin. Legend: A screen capture showing gene sets that match the string ‘cisplatin’ using the ‘GeneSet
Search’ tool in GW. The search returned 34 sets of which the three selected sets were chosen to create our set of conserved genes. Title:
Homologous Genes From Human, Mouse and Rat Related to Cisplatin. Legend: Results of the ‘HighSim’ graph tool in GW showing the number of
genes in each of the gene sets derived from CTD at the top of the figure and the number of genes in each of the set intersections going to the
bottom of the screen (analysis date 9/2/19). GeneWeaver gene-set identifiers for each of the intersections sets are shown below the boxes. The
96 genes resulting from the intersection of all three sets and the additional six from the MESH analysis comprise our set of conserved cisplatinresponsive genes. Abbreviations: H.s. = Homo sapiens, M.m. =Mus musculus, R.n. =Rattus norvegicus.

cisplatin can be traced back to three separate publications and three different species using the CTD resource
(Query performed on Sept. 3, 2019).
We selected three large data sets from CTD for further
analysis, one each from human, mouse and rat. The
selected sets consisted of 2386 (GS125959), 883
(GS257116) and 616 (GS263765) genes from human,
mouse and rat respectively. We chose these sets as
‘high-confidence’ sets because CTD data includes a large
corpus of gene-chemical associations curated from published literature [32].
To identify genes associated with biological processes
that are also evolutionarily conserved, and that therefore
could be considered central to the action of cisplatin, we
identified orthologous genes that share an association
with cisplatin in CTD.
To examine the orthologous gene overlap of these
species-specific sets, we used the GW Hierarchical Similarity (HiSim) Graph tool [33]. This tool creates a graph in
which leaves represent individual gene sets in the selection, and parent nodes represent sets of genes in the

intersection of all child nodes (analysis date 9/2/19).
Gene-overlap between mouse-human, rat-human and
mouse-rat sets were 378, 219 and 151 genes respectively.
We used the genes in the intersection of all three
cisplatin-response sets to generate a new gene set of the
96 human cisplatin-associated genes whose homologs are
conserved among the three species (GS271882) (Fig. 3).
To supplement the data from the human CTD gene set,
we performed the same analysis with an additional publically available gene set in GW, GS237976: [MeSH] Cisplatin:D002945. This analysis resulted in the identification
of six more conserved genes: GJA1, CCN1, H2AX, IL10,
WRN, HSP90AA1. Of these six genes only one, GJA1, was
differentially expressed in the TNBC subtypes. We included these additional genes in our analysis. Gene Sets
used for this study are listed in Table 1, for completeness
we include sets for MSL and IM in this table but they
were not used for further analysis.
Weaver gene-set identifier and the second column is
the number of genes in the set and the third column is
the gene-set title.
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Fig. 3 Title: Homologous Genes From Human, Mouse and Rat Related to Cisplatin Legend: Results of the ‘HighSim’ graph tool in GW showing
the number of genes in each of the gene sets derived from CTD at the top of the figure and the number of genes in each of the set
intersections going to the bottom of the screen (analysis date 9/2/19). GeneWeaver gene-set identifiers for each of the intersections sets are
shown below the boxes. The 96 genes resulting from the intersection of all three sets and the additional six from the MESH analysis comprise
our set of conserved cisplatin-responsive genes. Abbreviations: H.s. = Homo sapiens, M.m. =Mus musculus, R.n. =Rattus norvegicus.

Table 1 Gene Sets used for analysis in these studies. The first column is the Gene
GS ID

# of Genes

Gene Set Name

GS125959

2386

Cisplatin interacting with Homo sapiens associated genes (MeSH:D002945) in CTD

GS257116

883

GS257116: Cisplatin interacting with Mus musculus associated genes (MeSH:D002945) in CTD

GS263765

616

Cisplatin interacting with Rattus norvegicus associated genes (MeSH:D002945) in CTD

GS357326

378

Genes from CTD that interact with cisplatin and are conserved in human and mouse

GS357330

219

Genes from CTD that interact with cisplatin and are conserved in human and rat

GS357329

150

Genes from CTD that interact with cisplatin and are conserved in rat and mouse

GS271882

96

Genes from CTD that interact with cisplatin and are conserved in human, mouse and rat

GS237976

319

[MeSH] Cisplatin:D002945

GS271616

215

Genes upregulated in the BL1 subtype of triple negative breast cancer

GS271617

154

Genes upregulated in the BL2 subtype of triple negative breast cancer

GS271618

535

Genes upregulated in the IM subtype of triple negative breast cancer

GS271619

247

Genes upregulated in the M subtype of triple negative breast cancer

GS271621

805

Genes upregulated in LAR subtype of triple negative breast cancer

GS271724

829

Genes upregulated in the MSL subtype of triple negative breast cancer

GS271627

251

Genes downregulated in the BL1 subtype of triple negative breast cancer

GS271636

127

Genes downregulated in the BL2 subtype of triple negative breast cancer

GS271640

302

Genes downregulated in the IM subtype of triple negative breast cancer

GS271722

446

Genes downregulated in the M subtype of triple negative breast cancer

GS271729

382

Genes downregulated in the LAR subtype of triple negative breast cancer

GS271725

255

Genes downregulated in the MSL subtype of triple negative breast cancer
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Gene set analysis

Results

Gene sets were analyzed using the suite of tools from
the GeneWeaver resource [26]. As described above, we
used the ‘HiSim Graph’ tool to enumerate and visualize
intersections among the gene sets from human, mouse
and rat, and the ‘Boolean Algebra’ tool to create a set of
conserved genes representing the intersection of the
homologs of the three sets. We used the ‘Jaccard Similarity’ tool to statistically evaluate and identify genes in
the gene-set overlap between the set associated with cisplatin treatment, and sets of over- and under-expressed
genes in the TNBC subtypes. We used the default parameters for all analysis tools, details of which can be
found at the GeneWeaver.org website [33].

Gene sets of differentially expressed genes in TNBC
subtypes

Gene function analysis

To identify processes enriched in gene sets and represent them in a graphical format we used the Visual Annotation Display (VLAD) tool for Gene Ontology
enrichment analysis [34, 35]. First, to examine the 102
genes in the cisplatin-associated set we performed
VLAD analysis to determine if those genes were
enriched for processes known to represent cisplatin biology. We also tested the 20 cisplatin-associated genes that
were differentially regulated in TNBC subtypes to see if
their enrichment was different from the parental set,
which would have indicated that those genes were
enriched for a subset of processes that are involved in
cisplatin biology. In all analyses, we used default parameters for VLAD enrichment analysis, and the set of
UniProt-GOA human annotations as a background set
[36]. The analysis was run on September 2, 2019. The
UniProt-GOA gene annotation data used was dated
from February 26, 2018. Since GO annotations represent
processes that occur in normal cells and we are ultimately interested in the effects these genes have with respect to cisplatin treatment, we extended the functional
characterization of the cisplatin-associated genes that
are differentially regulated in resistant TNBC subtypes
by manually searching for evidence describing how they
might contribute to cisplatin reistance or sensitivity.
An additional functional analysis was performed with
the 102 genes in the cisplatin-associated set using the
KEGG Mapper Search Pathway tool to interrogate Pathways and Diseases [37]. Gene symbols were used with
default parameters in the Organism-specific search
mode (hsa). The analysis was performed on Sept 6, 2019.
We also ran an analysis using ‘String’, a network analysis tool that uses interaction data to functionally interrogate gene sets [38]. The analysis was performed on
Sept 8, 2019. Genes were entered using gene symbols,
analysis in human was selected and all default parameters were used. GO and KEGG catagories are reported
from the ‘Functional Analysis’ results.

To investigate sets of differentially regulated genes in
TNBC subtypes, we created gene sets in GW for the six
subtypes described by Lehmann et al [4]. We chose
these subtypes because the Lehmann analysis includes a
measure of relative sensitivity to cisplatin treatment.
Using the information from the supplemental data in
Lehmann et al, we associated their gene symbols with
unique HGNC identifiers to create 12 gene sets: i.e., an
up and down-expressed set for each of the six TNBC
subtypes (Table 1) [39]. The gene sets ranged in size
from 127 genes for which expression was down in the
BL2 subtype, to 829 genes where expression is up in the
MSL subtype. The 12 sets of up- and down-expressed
genes represents 2161 unique human genes. Thirty-five
genes were represented in 6 sets, and 101 genes were
contained in 5 sets. One gene, KRT17 (HGNC:6427),
was listed in both the up- and down-expressed sets of
MSL. For further analysis, we focused on the four TNBC
subtypes that represent subtypes that only contain
tumor-derived cells [12].
Cisplatin-associated genes are enriched for processes that
are consistent with the cytotoxic action and response to
cisplatin

We hypothesized that by creating a gene set of
evolutionarily-conserved cisplatin-interacting genes, we
would select for genes that function in the fundamental
actions of cisplatin. To test this, we used GO enrichment
analysis to determine which biological processes were
enriched in our 102 gene set. Our results confirm the
validity of our strategy: we identified a set of genes that
are involved in core cancer processes that are also
known to be associated with action of cisplatin. Specifically, VLAD analysis showed that the 102 conserved
cisplatin-associated genes were enriched for the GO biological processes: ‘aging’, ‘negative regulation of apoptotic process’, ‘apoptotic signaling pathway’, ‘response to
ionizing radiation’, ‘cellular response to oxidative stress’,
and ‘response to reactive oxygen species’ [Additional file 1: Table S1]. The 102 conserved genes were
also enriched for the GO cellular component terms
‘chromosome, telomeric region’, ‘mitochondrion’, ‘cytosol’, ‘extracellular space’ and ‘membrane raft’ [Additional
file 1: Table S1]. These results are consistent with the
known mechanism of cisplatin action in which cisplatin
causes oxidative stress, interacts with DNA and triggers
a response that culminates in apoptosis [40].
We extended our GO results by interrogating the
KEGG Pathway and KEGG Disease resources with the
102 conserved genes [41]. The KEGG Disease analysis
showed that our genes were most represented in a
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variety of different cancer types with esophageal cancer
associated with the most genes [5] [Additional file 2:
Table S2]. DNA excision repair was associated with four
genes and breast cancer was associated with two. The
top scorerer for the KEGG Pathway mapping analysis
was ‘cancer pathways’ (36 genes) [Additional file 3: Table
S3]. KEGG pathway analysis was also consistent with,
and confirmed the GO enrichment analysis: apoptosis
(27 genes), cellular senescence (21 genes) and stress response pathways like the P53 pathway (20 genes). The
KEGG analysis also identified several viral pathways as
well as the platinum drug resistance class (22 genes)
[Additional file 3: Table S3].
The set was interrogated using the String Network
analysis tool [38]. Functional groupings from String were
consistent with the VLAD and KEGG analysis results reported above [Additional file 4: Table S4].
A subset of cisplatin-associated differentially-expressed
genes provide a signature for the resistant subtypes

Of the 102 evolutionarily conserved cisplatin-assocated
genes, 20 are differentially expressed in TNBC subtypes
(Table 2). Using the Jaccard Similarity Tool in GW, we
compared the conserved set of cisplatin-responsive
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genes with the differentially expressed genes. Table 2
shows the summary of these data. Our results indicated
that of the 102 cisplatin-associated genes conserved in
human, mouse and rat, 16 genes were up-regulated in at
least one of the four subtypes and 11 were downregulated in at least one subtype.
Our results show that of the differentially expressed
genes in each subtype, only a small proportion are associated with the set of cisplatin-interacting genes: BL1 (2:
215 up and 5:251 down), BL2(4:154 up and 0:127 down),
M(5:247 up and 3:446 down), and LAR (8:805 up and 3:
382 down). If we examine only the set of genes that
show different expression behavior in the resistant LAR
and M subtypes when compared to the sensitive BL1
and BL2 subtypes, a signature of 13 genes is identified,
shown in column 6 of Table 2. These results show that
the differential expression of cisplatin-associated genes
in breast cancer subtypes involves only a small percentage, 20 genes, of the overall genes used to characterize
the subtypes and there is a set of 13 cisplatin-associated
genes whose differential expression is characteristic of
the two resistant subtypes.
The results of GO term enrichment analysis on the 20
differentially regulated genes for biological process are

Table 2 This table shows the 20 genes that are in the set of conserved cisplatin-responsive gene set, and how those genes are upand down-expressed in each of four Lehmann-identified TNBC subtypes. ‘UP’ indicates the gene is over-expressed and ‘DOWN’
indicates the gene is under-expressed. The ‘LAR’ or ‘M’ column indicates that the gene is differentially expressed in one of the two
cisplatin-resistant subtypes compared with the BL1 or BL2 sensitive subtypes. The ‘Cell Death’ column indicates if the gene has been
associated with a Gene Ontology term describing an aspect of cell death
Gene Symbol

Gene Name

BL1

BL2

M

ABCC2

ATP binding cassette subfamily C member 2

ADM

adrenomedullin

UP

UP

AKT1

AKT serine/threonine kinase 1

BCL2

BCL2 apoptosis regulator

BCL2L1

BCL2 like 1

CASP8

caspase 8

CAV1

caveolin 1

CLU

clusterin

FAS

Fas cell surface death receptor

FOS

Fos proto-oncogene, AP-1 transcription factor subunit

GSR

glutathione-disulfide reductase

GJA1

gap junction protein alpha 1

HSPB1

heat shock protein family B (small) member 1

MSH2

mutS homolog 2

UP

NOX4

NADPH oxidase 4

DOWN

NQO1

NAD(P)H quinone dehydrogenase 1

PTK2

protein tyrosine kinase 2

TUBA1A

tubulin alpha 1a

UP

VCAM1

vascular cell adhesion molecule 1

DOWN

VIM

vimentin

UP

LAR

Resistant

UP

*
*

UP

*

DOWN

*
*

DOWN

UP

*

*

UP

*

*

UP

*

UP

*

DOWN
DOWN

*

DOWN

*
*
*

UP
DOWN

Death

UP

*

UP

UP

*
UP
DOWN

UP

*
*

*

*

*

UP

*

*

DOWN

*

UP

*

*
DOWN

*
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shown in Additional file 5: Table S5 [Additional file 5:
Table S5]. Consistent with the conserved set of 102
cisplatin-associated genes, the 20 genes overlapping with
the TNBC differentially regulated sets were also enriched
for stress-response genes, aging, and genes that are involved in regulating programmed cell death. In addition
terms representing the ‘CD95-death inducing complex’
and focal adhesion complexes were enriched, consistent
with potential mechanisms of regulation of apoptosis
and epithelial-to-mesenchymal transition mitochondrial
outer membrane (p = 3.56e-05). Unlike the conserved set
of genes, these 20 genes are not as significantly enriched
for genes associated with telomeres (p = 1.1e-01) or nucleoplasm (p = 5.99e-02). This result shows that the subset of genes regulated in the TNBC subtypes are
enriched for similar processes as the parental sets and
are not biased towards other processes.
Genes that are differentially regulated in cisplatinresistant TNBC subtypes identify a variety of mechanisms
to escape cisplatin toxicity

To try to understand whether the differential regulation
of the 13 cisplatin-associated genes in the LAR and M
subtypes could explain the subtype’s resistance, we examined each gene individually to determine if there was
evidence that the over- or under-expression of these
genes correlated with resistance to cisplatin. The results
of our analysis are shown in Table 3, where the LAR and
M subtypes are shown to vary in their signature of cisplatin genes that are differentially regulated. Seven of the
genes are exclusively differentially expressed in the LAR
subtype, three in the M subtype and three are differentially expressed in both subtypes. Interestingly, the direction of the differential expression for the three common
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genes is in opposite directions. Examining how these
genes might influence cisplatin reistance shows that,
while some of the genes influence apoptosis directly,
others identify different upstream mechanisms of resistance. Since cisplatin is not a first-line treatment for
TNBC, most studies correlating these genes with resistance or sensitivity to cisplatin are from other cancer
types. Our results suggest that these genes may also influence cisplatin sensitivity in TNBC, and may help further elucidate the mechanisms of cisplatin action in
TNBC and suggest more refined strategies for cisplatin
treatment.

Discussion
We applied an integrated gene set analysis to identify
potential biological mechanisms underlying cisplatin
sensitivity in four different molecular subtypes of TNBC.
We defined a set of 102 cisplatin-associated genes conserved across human, mouse, and rat, and we used
knowledge about those genes to evaluate how those
genes could be involved in the therapeutic response.
Overall, our results show that many cisplatin-responsive
genes are involved with the end stage of the effects of
cisplatin treatment: cell death. Cell death is also the
most globally differentially regulated process identified
by cisplatin-responsive genes in all subtypes of TNBC.
These results imply that agents that up-regulate apoptotic signaling, such as Trail sensitizers, should be investigated as effective global co-therapies for cisplatin
treatment [66].
Response to Cisplatin

To specifically investigate the differences in cisplatin
response with respect to each of the subtypes, we

Table 3 This table shows genes that are differentially regulated when comparing the cisplatin-resistant versus cisplatin-sensitive
TNBC subtypes. Column 2 is a brief note about the action of the gene. Column 3 is a representative reference supporting the
mechanism
Gene Symbol

Evidence for Resistance

Reference

ABCC2 (up in LAR)

A transporter that when overexpressed results in cisplatin resistance

[42]

AKT1 (up in LAR)

A stress-response protein that when amplified or overexpressed is correlated with cisplatin resistance

[43, 44]

BCL2L1 (up in LAR)

Apoptosis-inhibitor, overexpression correlates with cisplatin resistance

[45, 46]

CASP8 (up in LAR down in M)

Required for cisplatin-associated apoptosis

[47, 48]

CLU (up in LAR)

Well known to contribute to chemoresistance including cisplatin

[49, 50]

FAS (down in M)

Overexpression induces cisplatin sensitivity and reduced expression correlates with resistance

[51–53]

GSR (up in LAR)

Involved in the detoxification of cisplatin

[54, 55]

MSH2 (down in LAR)

Required for cisplatin induced apoptosis

[56–58]

NOX4 (up in M)

Increased expression leads to more severe cisplatin toxicity

[37]

NQO1 (up in LAR)

A redox enzyme that has been show to contribute to resistance to cisplatin toxicity

[59–61]

TUBA1A (up in M down in LAR)

Correlated with cisplatin-reistance in esophageal cells

[62]

VCAM1 (down in M)

Associated with epithelial to mesenchymal transition overexpression contributes to cisplatin resistance

[63]

VIM (up in M down in LAR)

Associated with epithelial to mesenchymal transition

[64, 65]
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examined the genes that were uniquely differentially
expressed in the resistant LAR and M subtypes. Response to cisplatin can be modulated by a number of
different mechanisms: decreased cellular import or increased cellular efflux of cisplatin, detoxification of
cisplatin, defective DNA repair or resistance to cell
cycle arrest or cell death [25, 67, 68].
As noted previously, Lehmann et al showed that in
cell lines, the BL1 and BL2 subtypes often contained
mutations in one of the BRCA genes. They hypothesized that the DNA repair defect explained why BL1
and BL2 are more sensitive to cisplatin than the M or
LAR subtypes. It has recently been suggested that platins or PARP inhibitors are potential treatment options
for TNBC with BRCA mutations [17]. A recent study
by Zhao et al showed that other factors such as homologous recombination status may also influence
cisplatin response in breast cancer [69]. Our work suggests that in addition to BRCA mutation status, other
factors may contribute to differential sensitivity of these
subtypes. As described above, our results show that
cisplatin-associated genes involved in cell death are differentially expressed in all TNBC subtypes, but the
LAR and M subtypes have a unique signature of genes
that are not differentially regulated in the same way in
the BL1 or BL2 subtypes.
In particular, we find that the genes ABCC2, AKT1,
BCL2L1, CASP8, CLU, GSR, NQO1 are up-regulated in
the LAR subtype and MSH2 is downregulated. With the
exception of CASP8, the regulation of all of these genes
is consistent with reported resistance to cisplatin (Table
3). ABCC2 and GSR, specifically, represent a transporter
and a glutathione metabolic enzyme, respectively, that
lie in a pathway that detoxifies and transports cisplatin
out of the cell [42, 54]. The increase in ABCC2 and GSR,
and their actions upstream of the cell death related
genes, provides us with a testable hypothesis for an additional mechanism that contributes to the relative cisplatin resistance of the LAR subtype compared to the
other subtypes. That is to say, inhibition of either or
both of these proteins could make LAR cells more sensitive to cisplatin treatment (Fig. 4). AKT1, CLU and
NQO1 encode proteins that respond to stress, including
oxidative stress, which is one of the mechanisms of cisplatin action [70]. These three genes would contribute
to cisplatin resitance in pathways downstream of GSR or
ABCC2 [43, 49, 59–61]. BCL2L1 and CASP8 are both
proteins integral to the apoptotic program. BCL2L1 is an
inhibitor of apoptosis whose overexpression has been
correlated with cisplatin-resistance, consistent with its
upregulation in the resistant LAR subtype. The only
down-regulated gene, MSH2, is a protein involved in
DNA repair, although it has been shown to be necessary
for the apoptotic action of cisplatin [56, 57]. The up-
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regulation of CASP8 is counter-indicative of cisplatin resistance, since its overexpression has been shown to
make cells more sensitive to cisplatin [47]. However, it is
interesting to note that CASP8 would lie the most downstream of all of the other genes that are differentially
regulated in the LAR subtype and therefore may be epistatically masked by upstream changes.
The LAR subtype also shows differential regulation of
some genes also differentially regulated in the M subtype, but neither of the basal subtypes. VIM and TUBA1
are downregulated in the LAR subtype. Both VIM and
TUBA1 have previously been associated with cisplatin
resistance, but the causal effect remains to be determined [62, 64, 65]. In ovarian cancer cells downregulation of VIM expression resulted in resistance to
cisplatin by potentially down-regulating its import and
up-regulating its export, indicating that it might also be
contributing to cisplatin resistance in the LAR subtype
[64]. However, the factors controlling VIM expression
and its exact role in cisplatin resistance in different cancer types are still not well understood. Some studies, including some breast-cancer studies show increased VIM
expression correlates with cisplatin resistance [71–73].
One interesting question that arises from our analysis is
whether or not the LAR subtype represents a heterogeneous population that can be further subdivided with respect to mechanisms of resistance and if so, what is the
nature of the heterogeneity. Can some LAR tumors escape cisplatin by upregulating its transport out of the
cell while others escape by different mechanisms such as
upregulating GSR, or does a single tumor tend to accumulate multiple mechanisms of resistance? Because our
analysis is retrospective and used aggregate data from
previous studies, these types of questions require further
investigation.
In the M subtype, some genes differentially regulated
and potentially involved in cisplatin resistance differ
from those identified in the LAR subtype. To fully
understand the biology of cisplatin resistance in the M
subtype, one area to further pursue is the epithelial-tomesenchymal transition that results in increased VIM
expression, which is downregulated in the LAR subtype.
The M subtype also shows differential up-regulation of
VIM, NOX4 and TUBA1A. VCAM1 is downregulated in
the M subtype. VCAM1 has also been associated with an
increase in epithelial-to-mesenchymal transition and has
been correlated with resistance to cisplatin [63, 64].
Overexpression of VCAM1 has been shown to confer
cisplatin resistance in breast cancer cells [63]. The
downregulation of VCAM1 in the M subtype is counterintuitive to it being causative in this subtype’s lower sensitivity to cisplatin. As noted above, the expression of
VIM is less well understood. Although overexpression
correlates with cisplatin resistance in some contexts, it is
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Fig. 4 Title: Mechanisms of cisplatin-resistance in Four TNBC Subtypes. Legend: A schematic representation of the mechanisms by which a cell
can become resistant to the effects of cisplatin, and genes that are involved in those processes. Regulation of the expression of genes and their
direction of regulation is indicated for each of four TNBC subtypes described by Lehmann et al.

still not well characterized mechanistically. At least two
studies have shown that genes controlling the epithelialto-mesenchymal transition, ITGB1 and TET1, confer
cisplatin resistance, and those genes also increase the
expression of VIM [65, 73]. The gene sets of TNBC differentially expressed genes did not include ITGB1 or
TET1. NOX4 is an NADPH oxidase that generates reactive oxygen species and can make the effects of cisplatin
treatment more severe. However, overexpression of
NOX4 has been shown to result in normal breast cells
being resistant to apoptosis [74]. Like VCAM1, the
higher differential expression of NOX4 is counterindictive for cisplatin resistance. CASP8 is also downregulated
in the M subtype. In contrast to LAR, downregulation of
CASP8 in the M subtype would lead to a defect in the
apoptotic mechanism resulting in cisplatin resistance regardless of upstream triggers.

Conclusions
We have used a gene-set comparative approach to study
potential mechnisms of cisplatin resitance in TNBC subtypes. Out results show that in the resistant LAR subtype
a small number of genes that are differentially expressed
identify a variety of potential mechanisms that can be
used to escape cisplatin toxicity; transport, detoxification, and direct and indirect involvement in

programmed cell death. We hypothesize that the differential expression of these genes impacts how tumors of
a given subtype will respond to the agent. In the resistant M subtype, a small number of genes is also differentially regulated, but the interpretation of their
contribution to resistance is less clear. The differentially
regulated genes in the M subtype identify the epithelialto-mesenchymal transition and the control of reactive
oxygen species as potential regulators of cisplatin
response.
By focusing on genes known to be associated with cisplatin, our method identifies (or excludes) genes that
can serve as a signature in the differential response of
TNBC subtypes to cisplatin treatment. This gives an
advantage over global gene expression classification
systems in that we can pinpoint specific gene signatures
that classify with respect to a targeted area of interest, in this case with cisplatin association. Our results
suggest that additional therapies to enhance the apoptotic mechanism might be globally beneficial for the
treatment of all types of TNBC, while the LAR subtype might benefit from a combination treatment of
cisplatin and glutathione-modulator treatment agents
[75]. For TNBC the analysis could be extended to investigate the molecular basis of the differences in response to other primary therapeutic agents such as

Hill et al. BMC Cancer

(2019) 19:1039

taxane and anthracycline. One limitation to this extension
is availability of data for analysis. These types of studies require existing experimental data with respect to response
status and gene expression patterns for analysis and require high quality gene-chemical association data. In our
study, we used existing data reported for TNBC subtypes
and from the CTD resource to seed our analysis. As mentioned earlier, a limitation to this type of aggregate data is
that it does not allow us to ask questions with respect to
whether or not individual tumors or individual cells express different subsets of genes that confer resistance.
These types of questions can be addressed in future studies in which wet-bench studies of expression from tumor
samples or individual tumor cells are correlated with drug
resitance or sensitivity and are analyzed in the context of
high quality curated data about gene-chemical interactions. Ideally, a prospective strategy using markers such as
BRCA status or PD-L1 to predict response-type would be
most useful in deciding treatment options [17]. Our results identify genes that can be further studied as useful
biomarkers.
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